WallStreetZenWallStreetZen

NASDAQ: TCRX
Tscan Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for TCRX

Based on 2 analysts offering 12 month price targets for Tscan Therapeutics Inc

Min Forecast
$1.00+220.51%
Avg Forecast
$1.00+220.51%
Max Forecast
$1.00+220.51%

Should I buy or sell TCRX stock?

Based on 3 analysts offering ratings for Tscan Therapeutics Inc.

Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
3 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their TCRX stock forecasts and price targets.

TCRX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-09-08
lockedlocked$00.00+00.00%2026-09-03
lockedlocked$00.00+00.00%2026-09-02

1 of 1

Forecast return on equity

Is TCRX forecast to generate an efficient return?

Company
-62.1%
Industry
21.25%
Market
168.71%
TCRX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is TCRX forecast to generate an efficient return on assets?

Company
-25%
Industry
23.75%
TCRX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

TCRX earnings per share forecast

What is TCRX's earnings per share in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
-$0.91
Avg 2 year Forecast
-$1.02
Avg 3 year Forecast
-$0.84

TCRX revenue forecast

What is TCRX's revenue in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$5.6M-21.04%
Avg 2 year Forecast
$8.0M+12.63%
Avg 3 year Forecast
$22.4M+214.79%
TCRX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

TCRX revenue growth forecast

How is TCRX forecast to perform vs Biotechnology companies and vs the US market?

Company
41.32%
Industry
32.77%
Market
13.78%
TCRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
TCRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

TCRX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TCRX$0.31$1.00+220.51%Hold
JSPR$0.62$3.38+446.12%Buy
TVRD$1.63$7.33+349.88%Buy
ATOS$2.22$20.33+815.90%Strong Buy
NEUP$3.70N/AN/AHold
View Top Biotech Stocks

Tscan Therapeutics Stock Forecast FAQ

Is Tscan Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: TCRX) stock is to Hold TCRX stock.

Out of 3 analysts, 0 (0%) are recommending TCRX as a Strong Buy, 0 (0%) are recommending TCRX as a Buy, 3 (100%) are recommending TCRX as a Hold, 0 (0%) are recommending TCRX as a Sell, and 0 (0%) are recommending TCRX as a Strong Sell.

If you're new to stock investing, here's how to buy Tscan Therapeutics stock.

What is TCRX's earnings growth forecast for 2026-2028?

(NASDAQ: TCRX) Tscan Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.22%.

Tscan Therapeutics's earnings in 2026 is -$117,712,000.On average, 8 Wall Street analysts forecast TCRX's earnings for 2026 to be -$61,909,572, with the lowest TCRX earnings forecast at -$60,445,540, and the highest TCRX earnings forecast at -$62,628,032. On average, 8 Wall Street analysts forecast TCRX's earnings for 2027 to be -$69,270,399, with the lowest TCRX earnings forecast at -$75,722,984, and the highest TCRX earnings forecast at -$61,916,349.

In 2028, TCRX is forecast to generate -$56,690,569 in earnings, with the lowest earnings forecast at -$70,409,090 and the highest earnings forecast at -$41,989,248.

What is TCRX's revenue growth forecast for 2026-2028?

(NASDAQ: TCRX) Tscan Therapeutics's forecast annual revenue growth rate of 41.32% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.77%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.78%.

Tscan Therapeutics's revenue in 2026 is $7,111,000.On average, 8 Wall Street analysts forecast TCRX's revenue for 2026 to be $380,580,517, with the lowest TCRX revenue forecast at $135,016,276, and the highest TCRX revenue forecast at $771,531,260. On average, 7 Wall Street analysts forecast TCRX's revenue for 2027 to be $542,844,053, with the lowest TCRX revenue forecast at $332,118,350, and the highest TCRX revenue forecast at $810,097,656.

In 2028, TCRX is forecast to generate $1,517,238,623 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $3,378,050,290.

What is TCRX's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: TCRX) forecast ROA is -25%, which is lower than the forecast US Biotechnology industry average of 23.75%.

What is TCRX's Price Target?

According to 2 Wall Street analysts that have issued a 1 year TCRX price target, the average TCRX price target is $1.00, with the highest TCRX stock price forecast at $1.00 and the lowest TCRX stock price forecast at $1.00.

On average, Wall Street analysts predict that Tscan Therapeutics's share price could reach $1.00 by Sep 8, 2027. The average Tscan Therapeutics stock price prediction forecasts a potential upside of 220.51% from the current TCRX share price of $0.31.

What is TCRX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: TCRX) Tscan Therapeutics's current Earnings Per Share (EPS) is -$0.91. On average, analysts forecast that TCRX's EPS will be -$0.91 for 2026, with the lowest EPS forecast at -$0.89, and the highest EPS forecast at -$0.92. On average, analysts forecast that TCRX's EPS will be -$1.02 for 2027, with the lowest EPS forecast at -$1.12, and the highest EPS forecast at -$0.91. In 2028, TCRX's EPS is forecast to hit -$0.84 (min: -$1.04, max: -$0.62).

What is TCRX's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: TCRX) forecast ROE is -62.1%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.